Solange Peters, MD, PhD
Therapies that inhibit angiogenesis are attracting fresh interest in combination regimens with immune checkpoint immunotherapy in tumor types such as hepatocellular carcinoma (HCC), urothelial carcinoma, and endothelial cancer.
Peters reviewed data from 3 studies presented first at the 2018 American Society of Clinical Oncology Annual Meeting showing the progress investigators have made with these agents.
Figure. Process of Angiogenesis and Inhibition in Cancer
Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
PD-1/PD-L1 checkpoint inhibitors have been associated with promising activity as monotherapy in patients with HCC, and VEGF inhibition with bevacizumab has shown “modest activity” in this population. Based on positive results from phase III trials analyzing this combination in the first line for patients with renal cell carcinoma and non–small cell lung cancer, investigators hypothesized that bevacizumab might boost the efficacy of atezolizumab by “reversing VEGF-mediated immunosuppression and promoting T-cell infiltration into the tumor.”1
... to read the full story